Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores

2.

Hartwell

MJ

,

Özbek

U

,

Holler

E

, et al.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival

.

JCI Insight

.

2018

;

3

(

16

):

e89798

.

doi:10.1172/jci.insight.124015

.

3.

Gergoudis

SC

,

DeFilipp

Z

,

Özbek

U

, et al.

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

.

Blood Adv

.

2020

;

4

(

24

):

6098

-

6105

.

doi:10.1182/bloodadvances.2020003336

.

4.

Breit

SN

,

Wakefield

D

,

Robinson

JP

,

Luckhurst

E

,

Clark

P

,

Penny

R.

The role of alpha 1-antitrypsin deficiency in the pathogenesis of immune disorders

.

Clin Immunol Immunopathol

.

1985

;

35

(

3

):

363

-

380

.

doi:10.1016/0090-1229(85)90097-2

.

5.

Marcondes

AM

,

Hockenbery

D

,

Lesnikova

M

, et al.

Response of steroid-refractory acute GVHD to α1-antitrypsin

.

Biol Blood Marrow Transplant

.

2016

;

22

(

9

):

1596

-

1601

.

doi:10.1016/j.bbmt.2016.05.011

.

6.

Magenau

JM

,

Goldstein

SC

,

Peltier

D

, et al.

α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease

.

Blood

.

2018

;

131

(

12

):

1372

-

1379

.

doi:10.1182/blood-2017-11-815746

.

7.

Weissinger

EM

,

Metzger

J

,

Dobbelstein

C

, et al.

Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation

.

Leukemia

.

2014

;

28

(

4

):

842

-

852

.

doi:10.1038/leu.2013.210

.

8.

Weissinger

EM

,

Metzger

J

,

Schleuning

M

, et al.

A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

.

Leukemia

.

2021

;

35

(

6

):

1763

-

1772

.

doi:10.1038/s41375-020-01059-3

.

9.

Sormani

MP

,

Oneto

R

,

Bruno

B

, et al.

A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose

.

Bone Marrow Transplant

.

2003

;

32

(

2

):

205

-

211

.

doi:10.1038/sj.bmt.1704085

.

10.

Bacigalupo

A

,

Lamparelli

T

,

Milone

G

, et al;

Gruppo Italiano Trapianto Midollo Osseo (GITMO)

.

Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants

.

Bone Marrow Transplant

.

2010

;

45

(

2

):

385

-

391

.

doi:10.1038/bmt.2009.151

.

11.

Luft

T

,

Benner

A

,

Jodele

S

, et al.

EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis

.

Lancet Haematol

.

2017

;

4

(

9

):

e414

-

e423

.

doi:10.1016/s2352-3026(17)30108-4

.

12.

Jiang

S

,

Penack

O

,

Terzer

T

, et al.

Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel

.

Haematologica

.

2021

;

106

(

2

):

446

-

453

.

doi:10.3324/haematol.2019.238790

.

13.

Peña

M

,

Salas

MQ

,

Mussetti

A

, et al.

Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation

.

Blood Adv

.

2021

;

5

(

17

):

3418

-

3426

.

doi:10.1182/bloodadvances.2021004812

.

14.

Varma

A

,

Rondon

G

,

Srour

SA

, et al.

Endothelial activation and stress index (EASIX) at admission predicts fluid overload in recipients of allogeneic stem cell transplantation

.

Biol Blood Marrow Transplant

.

2020

;

26

(

5

):

1013

-

1020

.

doi:10.1016/j.bbmt.2020.01.028

.

15.

Sanchez-Escamilla

M

,

Flynn

J

,

Devlin

S

, et al.

EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation

.

Bone Marrow Transplant

.

2023

;

58

(

5

):

498

-

505

.

doi:10.1038/s41409-023-01922-8

.

16.

Mariotti

J

,

Magri

F

,

Giordano

L

, et al.

EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide

.

Bone Marrow Transplant

.

2023

;

58

(

3

):

247

-

256

.

doi:10.1038/s41409-022-01874-5

.

17.

Luft

T

,

Benner

A

,

Terzer

T

, et al.

EASIX and mortality after allogeneic stem cell transplantation

.

Bone Marrow Transpl

.

2020

;

55

(

3

):

553

-

561

.

doi:10.13039/501100001659

.

18.

Nawas

MT

,

Sanchez-Escamilla

M

,

Devlin

SM

, et al.

Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation

.

Blood Adv

.

2022

;

6

(

22

):

5898

-

5907

.

doi:10.1182/bloodadvances.2022007381

.

19.

Choi

J

,

Cooper

ML

,

Alahmari

B

, et al.

Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect

.

PLoS One

.

2014

;

9

(

10

):

e109799

.

doi:10.1371/journal.pone.0109799

.

20.

Ponce

DM

,

Alousi

AM

,

Nakamura

R

, et al.

A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GvHD of the lower GI tract

.

Blood

.

2023

;

141

(

12

):

1389

-

1401

.

doi:10.1182/blood.2021015111

.

21.

Yu

X

,

Ma

H

,

Li

B

, et al.

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis

.

Blood

.

2023

;

141

(

9

):

1070

-

1086

.

doi:10.1182/blood.2022017262

.

22.

Van Lier

YF

,

Vos

J

,

Blom

B

,

Hazenberg

MD

.

Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease

.

Gut Microbes

.

2023

;

15

(

1

):

2178805

.

doi:10.1080/19490976.2023.2178805

.

23.

Pasquini

MC

,

Logan

B

,

Jones

RJ

, et al.

Blood and marrow transplant clinical trials network report on the development of novel endpoints and selection of promising approaches for graft-versus-host disease prevention trials

.

Biol Blood Marrow Transplant

.

2018

;

24

(

6

):

1274

-

1280

.

doi:10.1016/j.bbmt.2018.01.002

.

24.

Cuvelier

GDE

,

Nemecek

ER

,

Wahlstrom

JT

, et al.

Benefits and challenges with diagnosing chronic and late acute GvHD in children using the NIH consensus criteria

.

Blood

.

2019

;

134

(

3

):

304

-

316

.

doi:10.1182/blood.2019000216

.

25.

Locatelli

F

,

Bauquet

A

,

Palumbo

G

,

Moretta

F

,

Bertaina

A.

Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation

.

Immunol Lett

.

2013

;

155

(

1-2

):

21

-

23

.

doi:10.1016/j.imlet.2013.09.027

.

26.

Bleakley

M.

Naive T-cell depletion in stem cell transplantation

.

Blood Adv

.

2020

;

4

(

19

):

4980

.

doi:10.1182/bloodadvances.2020001888

.

27.

Yu

J

,

Storer

BE

,

Kushekhar

K

, et al.

Biomarker panel for chronic graft-versus-host disease

.

J Clin Oncol

.

2016

;

34

(

22

):

2583

-

2590

.

doi:10.1200/jco.2015.65.9615

.

28.

Subburaj

D

,

Ng

B

,

Kariminia

A

, et al.

Metabolomic identification of α- ketoglutaric acid elevation in pediatric chronic graft-versus-host disease

.

Blood

.

2022

;

139

(

2

):

287

-

299

.

doi:10.1182/blood.2021013244

.

29.

Schultz

KR

,

Kariminia

A

,

Ng

B

, et al.

Immune profile differences between chronic GvHD and late acute GvHD: results of the ABLE/PBMTC 1202 studies

.

Blood

.

2020

;

135

(

15

):

1287

-

1298

.

doi:10.1182/blood.2019003186

.

30.

Paczesny

S

,

Hakim

FT

,

Pidala

J

, et al.

National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2014 Biomarker Working Group Report

.

Biol Blood Marrow Transplant

.

2015

;

21

(

5

):

780

-

792

.

doi:10.1016/j.bbmt.2015.01.003

.

31.

Cuvelier

GDE

,

Ng

B

,

Abdossamadi

S

, et al.

A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study

.

Blood Adv

.

2023

;

7

(

14

):

3612

-

3623

.

doi:10.1182/bloodadvances.2022007715

.

32.

Cuvelier

GDE

,

Schoettler

M

,

Buxbaum

NP

, et al.

Toward a better understanding of the atypical features of chronic graft-versus-host disease: a report from the 2020 National Institutes of Health Consensus Project Task Force

.

Transplant Cell Ther

.

2022

;

28

(

8

):

426

-

445

.

doi:10.1016/j.jtct.2022.05.038

.

33.

Ng

B

,

Cuvelier

GDE

,

Abdossamadi

S

,

Ostroumov

E

,

Kariminia

A

,

Schultz

KR

.

Machine learning-based identification of two distinct immune profiles of chronic GvHD in children with the prospective ABLE 1.0 Study Cohort EBMT meeting

April 26

,

Paris, France

,

2023

.

34.

Ng

B

,

Cuvelier

GDE

,

Abdossamadi

S

,

Ostroumov

E

,

Kariminia

A

,

Schultz

KR

. Two distinct immune profiles are identified in pediatric chronic GvHD by machine learning in the ABLE Study Cohort EBMT meeting

April

25

,

Paris, France

,

2023

.

35.

Iwasaki

M

,

Kanda

J

,

Arai

Y

, et al.

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning

.

Blood Adv

.

2022

;

6

(

8

):

2618

-

2627

.

doi:10.1182/bloodadvances.2021005800

.

36.

Arora

M

,

Klein

JP

,

Weisdorf

DJ

, et al.

Chronic GVHD risk score: a center for international blood and marrow transplant research analysis

.

Blood

.

2011

;

117

(

24

):

6714

-

6720

.

doi:10.1182/blood-2010-12-323824

.

37.

Rayment

JH

,

Sandoval

RA

,

Roden

JP

,

Schultz

KR

.

Multiple breath washout testing to identify pulmonary chronic graft versus host disease in children after haematopoietic stem cell transplantation

.

Transplant Cell Ther

.

2022

;

28

(

6

):

328.e1

-

328.e7

.

doi:10.1016/j.jtct.2022.02.002

.

38.

Tamburro

RF

,

Cooke

KR

,

Davies

SM

, et al;

Pulmonary complications of pediatric hematopoietic stem cell transplantation workshop participants

.

Pulmonary complications of pediatric hematopoietic cell transplantation. A National Institutes of Health Workshop Summary

.

Ann Am Thorac Soc

.

2021

;

18

(

3

):

381

-

394

.

doi:10.1513/AnnalsATS.202001-006OT

.

39.

Alborghetti

MR

,

Correa

MEP

,

Whangbo

J

, et al.

Clinical metabolomics identifies blood serum branched chain amino acids as potential predictive biomarkers for chronic graft vs. host disease

.

Front Oncol

.

2019

;

9

:

141

.

doi:10.3389/fonc.2019.00141

.

40.

Markey

KA

,

Schluter

J

,

Gomes

ALC

, et al.

The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD

.

Blood

.

2020

;

136

(

1

):

130

-

136

.

doi:10.1182/blood.2019003369

.

41.

Arai

S

,

Sahaf

B

,

Narasimhan

B

, et al.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence

.

Blood

.

2012

;

119

(

25

):

6145

-

6154

.

doi:10.1182/blood-2011-12-395970

.